Patents by Inventor Shigeru Kinoshita
Shigeru Kinoshita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11918630Abstract: The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (?4?1?1), laminin 511 (?5?1?1), laminin 521 (?5?2?1), or fragments of these.Type: GrantFiled: October 30, 2015Date of Patent: March 5, 2024Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
-
Patent number: 11839618Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: GrantFiled: October 9, 2015Date of Patent: December 12, 2023Assignees: SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
-
A STORAGE METHOD OF HUMAN CORNEAL ENDOTHELIAL CELLS AND/OR HUMAN CORNEAL ENDOTHELIAL PRECURSOR CELLS
Publication number: 20230380417Abstract: Human corneal endothelial cells and/or human corneal endothelial precursor cells are preserved with a high survival rate of these cells being maintained, and the occurrence rate of contaminated cells in post-preservation culturing is suppressed. A storage method of human corneal endothelial cells and/or human corneal endothelial precursor cells is characterized in that human corneal endothelial cells and/or human corneal endothelial precursor cells that have been cultured using a culture medium that contains a ROCK inhibitor, and in which the content of epidermal growth factor (EGF) is less than a concentration that will cause a transformation are harvested at a timing when any one of or a plurality of the conditions (a)˜(d) have been met, and are placed in a suspension state and then preserved.Type: ApplicationFiled: October 19, 2021Publication date: November 30, 2023Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Shigeru KINOSHITA, Munetoyo TODA, Chie SOTOZONO, Morio UENO -
Publication number: 20230310402Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.Type: ApplicationFiled: June 7, 2023Publication date: October 5, 2023Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Publication number: 20230295801Abstract: According to one embodiment, a film forming method includes alternately performing a first process including at least two times of a first sequence and a second process including at least one time of a second sequence. The first sequence includes supplying a film forming gas into a film forming chamber, supplying a first purge gas into the film forming chamber, supplying a first reduction gas into the film forming chamber, and supplying a second purge gas into the film forming chamber, in order, and the second sequence includes supplying a second reduction gas into the film forming chamber, and supplying a third purge gas into the film forming chamber, in order.Type: ApplicationFiled: September 13, 2022Publication date: September 21, 2023Applicant: Kioxia CorporationInventors: Shigeru KINOSHITA, Hiroshi TOYODA, Satoshi WAKATSUKI, Masayuki KITAMURA, Naomi FUKUMAKI
-
Patent number: 11730722Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.Type: GrantFiled: July 30, 2013Date of Patent: August 22, 2023Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
-
Publication number: 20230257700Abstract: To provide a cell trait assay technique for identifying cultured human corneal endothelium cells of which early clinical effect manifestation and a long-term stable clinical effect are confirmed, in clinical trials. Provided is a method of manufacturing a functional human corneal endothelial cell capable of eliciting a human corneal function when infused into an anterior chamber of a human eye, the method comprising the step of proliferating and/or differentiating or maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress, such as proliferation stress.Type: ApplicationFiled: February 26, 2021Publication date: August 17, 2023Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Shigeru KINOSHITA, Junji HAMURO, Chie SOTOZONO, Morio UENO, Munetoyo TODA
-
Publication number: 20230214998Abstract: A cell evaluation method evaluates the quality of a cell population including a plurality of cells. The cell evaluation method comprises: an index calculation step of calculating an index, based on a captured image of the cell population, the index including at least any one of an average distance representing a packing degree of the cells, a spring constant representing a degree of consistency in distances between the cells, and a hexagonal order parameter representing a degree to which an arrangement of the cells resembles a regular hexagon; and an evaluation step of evaluating the cell population, based on the index calculated in the index calculation step.Type: ApplicationFiled: July 29, 2022Publication date: July 6, 2023Applicants: Kyoto University, Kyoto Prefectural Public University CorporationInventors: Motomu Tanaka, Akihisa Yamamoto, Morio Ueno, Junji Hamuro, Shigeru Kinoshita, Hiroshi Tanaka, Munetoyo Toda, Chie Sotozono
-
Publication number: 20230210864Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: ApplicationFiled: March 13, 2023Publication date: July 6, 2023Applicants: Senju Pharmaceutical Co., Ltd.Inventors: Noriko KOIZUMI, Shigeru KINOSHITA, Morio UENO
-
Patent number: 11633477Abstract: The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (?5?1?1), laminin 521 (?5?2?1), or a fragment of these.Type: GrantFiled: October 30, 2015Date of Patent: April 25, 2023Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
-
Patent number: 11633404Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: GrantFiled: October 9, 2015Date of Patent: April 25, 2023Assignees: SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
-
Patent number: 11624053Abstract: The present invention provides a method of culturing corneal endothelial cells. More specifically, the present invention provides a composition for culturing or growing corneal endothelial cells, comprising at least one agent consisting of laminins and fragments thereof which express in corneal endothelial cells. Specifically, the present invention can comprise laminin 511 (alpha5 beta1 gamma1) and laminin 512 (alpha5 beta2 gamma 1). The present invention further provides a culture container for corneal endothelial cells, which is coated with the composition of the present invention. Furthermore, the present invention provides a method for culturing corneal endothelial cells comprising the step of using the composition or the container of the present invention to culture the corneal endothelial cells.Type: GrantFiled: November 26, 2014Date of Patent: April 11, 2023Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, ActualEyes Inc., CorneaGen, Inc.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita, Friedrich E. Kruse, Ursula Schloetzer-Schrehardt
-
Publication number: 20230057984Abstract: The present invention provides a method for the normalized culturing of corneal endothelial cells. More specifically, the present invention provides a culture-normalizing-agent of a corneal endothelial cell, comprising a fibrosis inhibitor. In detail, the present invention provides a culture-normalizing agent comprising a transforming growth factor (TGF) ? signal inhibitor. The present invention also provides a culture medium for culturing a corneal endothelial cell normally, which comprises the culture-normalizing agent according to the present invention and corneal endothelium culture components. The present invention also provides a method for culturing a corneal endothelial cell normally, comprising the step of culturing a corneal endothelial cell using the culture-normalizing agent according to the present invention or the culture medium according to the present invention.Type: ApplicationFiled: September 28, 2022Publication date: February 23, 2023Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, ActualEyes Inc., CorneaGen, Inc.Inventors: Shigeru KINOSHITA, Noriko KOIZUMI, Naoki OKUMURA
-
Patent number: 11479754Abstract: A method for producing an epithelial cell sheet, comprising culturing cells derived from oral mucosal epithelial cells on a substrate in a serum-free medium, wherein the serum-free medium comprises (i) EGF protein or KGF protein, (ii) B-27 supplement, and (iii) a ROCK inhibitor.Type: GrantFiled: April 19, 2017Date of Patent: October 25, 2022Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Takahiro Nakamura, Shigeru Kinoshita, Seiichi Yokoo, Satoru Yamagami
-
Patent number: 11469127Abstract: A substrate processing device according to the present embodiment includes a processing tank configured to be capable of accumulating a liquid. A conveyer can array a plurality of semiconductor substrates in such a manner that front surfaces of the semiconductor substrates face a substantially horizontal direction, and transport the semiconductor substrates into the processing tank. A plurality of liquid suppliers can supply the liquid toward an inside of the processing tank from a lower portion of the processing tank. A plurality of current plates are arranged on at least either one end side or the other end side of an array of the semiconductor substrates. The current plates are provided in a first gap region above the semiconductor substrates in gaps between the conveyer and a sidewall of the processing tank on both sides of the conveyer as viewed from an array direction of the semiconductor substrates.Type: GrantFiled: July 17, 2020Date of Patent: October 11, 2022Assignee: Kioxia CorporationInventors: Shigeru Kinoshita, Shusaku Matsumoto, Koichiro Kawano, Hiroshi Fujita, Yoshinori Kitamura
-
Publication number: 20220296580Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF?-signal inhibitor. As a preferred TGF?-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.Type: ApplicationFiled: June 3, 2022Publication date: September 22, 2022Applicants: Kyoto Prefectural Public University Corporation, The Doshisha, Senju Pharmaceutical Co., Ltd.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Publication number: 20220293620Abstract: A semiconductor memory device comprises: a first conductive and second conductive layers extending in a first direction; and first and second semiconductor column rows aligned in a second direction. The first semiconductor column rows each comprise first semiconductor columns aligned in the first direction and facing the first conductive layer. The second semiconductor column rows each comprise second semiconductor columns aligned in the first direction and facing the second conductive layer. For example, a distance in the first direction between center positions of two of the first semiconductor columns adjacent in the first direction is assumed to be a first adjacent distance. In this case, a pitch in the second direction of the first semiconductor column rows is ?3/2 or more times the first adjacent distance. Moreover, a pitch in the second direction of the second semiconductor column rows is less than ?3/2 times the first adjacent distance.Type: ApplicationFiled: August 23, 2021Publication date: September 15, 2022Applicant: Kioxia CorporationInventor: Shigeru KINOSHITA
-
Cell evaluation method, cell evaluation device, and recording medium storing cell evaluation program
Patent number: 11436719Abstract: A cell evaluation method evaluates the quality of a cell population including a plurality of cells. The cell evaluation method comprises: an index calculation step of calculating an index, based on a captured image of the cell population, the index including at least any one of an average distance representing a packing degree of the cells, a spring constant representing a degree of consistency in distances between the cells, and a hexagonal order parameter representing a degree to which an arrangement of the cells resembles a regular hexagon; and an evaluation step of evaluating the cell population, based on the index calculated in the index calculation step.Type: GrantFiled: February 15, 2018Date of Patent: September 6, 2022Assignees: Kyoto University, Kyoto Prefectural Public University CorporationInventors: Motomu Tanaka, Akihisa Yamamoto, Morio Ueno, Junji Hamuro, Shigeru Kinoshita, Hiroshi Tanaka, Munetoyo Toda, Chie Sotozono -
Patent number: 11382904Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF?-signal inhibitor. As a preferred TGF?-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.Type: GrantFiled: October 30, 2014Date of Patent: July 12, 2022Assignees: Kyoto Prefectural Public University Corporation, The Doshisha, Senju Pharmaceutical Co., Ltd.Inventors: Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
-
Publication number: 20220085053Abstract: According to one embodiment, a semiconductor device includes: a stacked body including an insulating layer, and a conductive layer containing molybdenum; an aluminum oxide layer provided between the insulating layer and the conductive layer; and a protective layer in contact with the aluminum oxide layer, containing one of carbon, nitrogen, or sulfur bonded to aluminum in the aluminum oxide layer, and also in contact with the conductive layer.Type: ApplicationFiled: September 3, 2021Publication date: March 17, 2022Applicant: Kioxia CorporationInventors: Masayuki KITAMURA, Takuya HIROHASHI, Shigeru KINOSHITA, Hiroshi TOYOTA